KYMR
NASDAQKymera Therapeutics Inc.
Price$98.22+2.70 (+2.83%)
01:30 PM07:45 PM
News · 26 weeks108+36%
2025-12-282026-06-21
Mix6590d
- SEC Filings31(48%)
- Insider18(28%)
- Other11(17%)
- Earnings2(3%)
- Leadership2(3%)
- Analyst1(2%)
Latest news
25 items- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERDirector Booth Bruce sold $3,299,037 worth of shares (31,798 units at $103.75) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERDirector Booth Bruce exercised 11,741 shares at a strike of $20.00 and sold $45,293,294 worth of shares (478,198 units at $94.72) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Business Officer Goodman Noah exercised 2,500 shares at a strike of $21.05 and sold $247,500 worth of shares (2,500 units at $99.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- PRKymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual MeetingOral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the results from the Phase 1 study of KT-621, its first-in-class, oral STAT6 degrader, in healthy Japa
- PRKymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi CollaborationFirst-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the first participant has been dosed in the first-in-human Phase 1 clinical trial evaluating KT-485 (SAR447971), an oral, potent and selective IRAK4 degrader, in adult healthy volunteers and hidradenitis suppurativa (HS) patients. The Phase 1 trial (NCT07629336) is being conducted by the Company's partner Sanofi. Under th
- SECSEC Form 8-K filed by Kymera Therapeutics Inc.8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
- PRKymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development OperationsPenny Carlson will oversee global clinical development operations across Kymera's oral immunology portfolio Jeremy Chadwick will retire from his role as Chief Operating Officer WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Penny Carlson as Senior Vice President, Development Operations. Ms. Carlson brings more than two decades of biopharmaceutical leadership experience across clinical program management, study execution and data management, with a track record of advancing n
- PRKymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS CongressesKT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer trial ongoing, with data expected in 2H26 WATERTOWN, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the presentation of new preclinical data for KT-579, its potent, selective, oral IRF5 degrader, demonstrating disease-modifying activity in lupus models. The findings show that by selectively targeting and degradin
- INSIDERChief Financial Officer Jacobs Bruce N. exercised 12,653 shares at a strike of $2.08, increasing direct ownership by 5% to 260,241 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Operating Officer Chadwick Jeremy G sold $1,373,290 worth of shares (17,184 units at $79.92) as part of a pre-agreed trading plan, decreasing direct ownership by 28% to 44,018 units (SEC Form 4) to satisfy withholding obligation4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- PRKymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare ConferenceWATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on June 3, 2026, at 8:10 a.m. ET. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pion
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERDirector Esposito Pamela exercised 1,000 shares at a strike of $31.20 (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Financial Officer Jacobs Bruce N. exercised 15,000 shares at a strike of $2.08, increasing direct ownership by 6% to 247,588 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
KYMR FAQ
7 questionsWhat does Kymera Therapeutics Inc. do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid...Where does KYMR stock trade?
Kymera Therapeutics Inc. (KYMR) is listed on NASDAQ.What sector and industry is KYMR in?
Kymera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kymera Therapeutics Inc. go public?
Kymera Therapeutics Inc. (KYMR) completed its IPO in 2020.What are analysts saying about KYMR?
Kymera Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-05-06.What companies are similar to KYMR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare KYMR side-by-side with any of them on Quantisnow.How can I track KYMR on Quantisnow?
Quantisnow aggregates Kymera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYMR to receive live email and push alerts on every new disclosure.